AUR108
/ Dr. Reddy’s, Servier
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 18, 2026
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Trial primary completion date: Aug 2025 ➔ Aug 2027
First-in-human • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology
January 31, 2024
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Lymphoma • Oncology
August 09, 2023
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Aurigene Discovery Technologies Limited
Metastases • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 3
Of
3
Go to page
1